|
1
|
Raab MS, Podar K, Breitkreutz I,
Richardson PG and Anderson KC: Multiple myeloma. Lancet.
374:324–339. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bladé J, Cibeira MT and Rosiñol L: Novel
drugs for the treatment of multiple myeloma. Haematologica.
95:702–704. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rajkumar SV: Treatment of multiple
myeloma. Nat Rev Clin Oncol. 8:479–491. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang X, Zhang M, Wang M, He P, Liu X, Chen
L, Xi J, Wang M, Li J, Liu H, et al: Arsenic trioxide combined with
VCMP or VAD chemotherapy in patients with refractory or relapsed
multiple myeloma in a single institution of China. Indian J Hematol
Blood Transfus. 30:259–264. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Paramore A and Frantz S: Bortezomib. Nat
Rev Drug Discov. 2:611–612. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sethi G, Sung B and Aggarwal BB: Nuclear
factor-kappaB activation: From bench to bedside. Exp Biol Med
(Maywood). 233:21–31. 2008. View Article : Google Scholar
|
|
7
|
Tsubaki M, Takeda T, Ogawa N, Sakamoto K,
Shimaoka H, Fujita A, Itoh T, Imano M, Ishizaka T, Satou T, et al:
Over-expression of survivin via activation of ERK1/2, Akt, and
NF-κB plays a central role in vincristine resistance in multiple
myeloma cells. Leuk Res. 39:445–452. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cormier F, Monjanel H, Fabre C, Billot K,
Sapharikas E, Chereau F, Bordereaux D, Molina TJ, Avet-Loiseau H
and Baud V: Frequent engagement of RelB activation is critical for
cell survival in multiple myeloma. PLoS One. 8:e591272013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Karin M and Greten FR: NF-kappaB: Linking
inflammation and immunity to cancer development and progression.
Nat Rev Immunol. 5:749–759. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ma C, Zuo W, Wang X, Wei L, Guo Q and Song
X: Lapatinib inhibits the activation of NF-κB through reducing
phosphorylation of IκB-α in breast cancer cells. Oncol Rep.
29:812–818. 2013.
|
|
11
|
Hideshima T, Ikeda H, Chauhan D, Okawa Y,
Raje N, Podar K, Mitsiades C, Munshi NC, Richardson PG, Carrasco
RD, et al: Bortezomib induces canonical nuclear factor-kappaB
activation in multiple myeloma cells. Blood. 114:1046–1052. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hayden MS and Ghosh S: Shared principles
in NF-kappaB signaling. Cell. 132:344–362. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Panwalkar A, Verstovsek S and Giles F:
Nuclear factor-kappaB modulation as a therapeutic approach in
hematologic malignancies. Cancer. 100:1578–1589. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Joyce D, Albanese C, Steer J, Fu M,
Bouzahzah B and Pestell RG: NF-kappaB and cell-cycle regulation:
The cyclin connection. Cytokine Growth Factor Rev. 12:73–90. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tsubaki M, Ogawa N, Takeda T, Sakamoto K,
Shimaoka H, Fujita A, Itoh T, Imano M, Satou T and Nishida S:
Dimethyl fumarate induces apoptosis of hematopoietic tumor cells
via inhibition of NF-κB nuclear translocation and down-regulation
of Bcl-xL and XIAP. Biomed Pharmacother. 68:999–1005. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Olaku O and White JD: Herbal therapy use
by cancer patients: A literature review on case reports. Eur J
Cancer. 47:508–514. 2011. View Article : Google Scholar :
|
|
17
|
Jeong SJ, Koh W, Kim B and Kim SH: Are
there new therapeutic options for treating lung cancer based on
herbal medicines and their metabolites? J Ethnopharmacol.
138:652–661. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang LH, Li Y, Yang SN, Wang FY, Hou Y,
Cui W, Chen K, Cao Q, Wang S, Zhang TY, et al: Gambogic acid
synergistically potentiates cisplatin-induced apoptosis in
non-small-cell lung cancer through suppressing NF-κB and MAPK/HO-1
signalling. Br J Cancer. 110:341–352. 2014. View Article : Google Scholar :
|
|
19
|
Luo F, Lv Q, Zhao Y, Hu G, Huang G, Zhang
J, Sun C, Li X and Chen K: Quantification and purification of
mangiferin from Chinese Mango (Mangifera indica L.) cultivars and
its protective effect on human umbilical vein endothelial cells
under H(2)O(2)-induced stress. Int J Mol Sci. 13:11260–11274. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shoji K, Tsubaki M, Yamazoe Y, Satou T,
Itoh T, Kidera Y, Tanimori Y, Yanae M, Matsuda H, Taga A, et al:
Mangiferin induces apoptosis by suppressing Bcl-xL and XIAP
expressions and nuclear entry of NF-κB in HL-60 cells. Arch Pharm
Res. 34:469–475. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Slawinska-Brych A, Zdzisinska B,
Mizerska-Dudka M and Kandefer-Szerszen M: Induction of apoptosis in
multiple myeloma cells by a statin-thalidomide combination can be
enhanced by p38 MAPK inhibition. Leuk Res. 37:586–594. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kannaiyan R, Hay HS, Rajendran P, Li F,
Shanmugam MK, Vali S, Abbasi T, Kapoor S, Sharma A, Kumar AP, et
al: Celastrol inhibits proliferation and induces chemosensitization
through down-regulation of NF-κB and STAT3 regulated gene products
in multiple myeloma cells. Br J Pharmacol. 164:1506–1521. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tsubaki M, Komai M, Itoh T, Imano M,
Sakamoto K, Shimaoka H, Ogawa N, Mashimo K, Fujiwara D, Takeda T,
et al: Inhibition of the tumour necrosis factor-alpha autocrine
loop enhances the sensitivity of multiple myeloma cells to
anticancer drugs. Eur J Cancer. 49:3708–3717. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
du Plessis-Stoman D, du Preez J and van de
Venter M: Combination treatment with oxaliplatin and mangiferin
causes increased apoptosis and downregulation of NFκB in cancer
cell lines. Afr J Tradit Complement Altern Med. 8:177–184.
2011.
|
|
25
|
Trocoli A and Djavaheri-Mergny M: The
complex interplay between autophagy and NF-κB signaling pathways in
cancer cells. Am J Cancer Res. 1:629–649. 2011.
|
|
26
|
DiDonato JA, Mercurio F and Karin M: NF-κB
and the link between inflammation and cancer. Immunol Rev.
246:379–400. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhu HJ, Liu L, Fan L, Zhang LN, Fang C,
Zou ZJ, Li JY and Xu W: The BH3-only protein Puma plays an
essential role in p53-mediated apoptosis of chronic lymphocytic
leukemia cells. Leuk Lymphoma. 54:2712–2719. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tsubaki M, Satou T, Itoh T, Imano M, Komai
M, Nishinobo M, Yamashita M, Yanae M, Yamazoe Y and Nishida S:
Over-expression of MDR1 and survivin, and decreased Bim expression
mediate multidrug-resistance in multiple myeloma cells. Leuk Res.
36:1315–1322. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tsubaki M, Komai M, Itoh T, Imano M,
Sakamoto K, Shimaoka H, Takeda T, Ogawa N, Mashimo K, Fujiwara D,
et al: By inhibiting Src, verapamil and dasatinib overcome
multidrug resistance via increased expression of Bim and decreased
expressions of MDR1 and survivin in human multidrug-resistant
myeloma cells. Leuk Res. 38:121–130. 2014. View Article : Google Scholar
|
|
30
|
Markovic O, Marisavljevic D,
Cemerikic-Martinovic V, Martinovic T, Filipovic B, Stanisavljevic
D, Zivković R, Hajder J, Stanisavljevic N and Mihaljevic B:
Survivin expression in patients with newly diagnosed nodal diffuse
large B cell lymphoma (DLBCL). Med Oncol. 29:3515–3521. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Desplanques G, Giuliani N, Delsignore R,
Rizzoli V, Bataille R and Barillé-Nion S: Impact of XIAP protein
levels on the survival of myeloma cells. Haematologica. 94:87–93.
2009. View Article : Google Scholar :
|
|
32
|
Lin J, Wu Y, Yang D and Zhao Y: Induction
of apoptosis and antitumor effects of a small molecule inhibitor of
Bcl-2 and Bcl-xl, gossypol acetate, in multiple myeloma in vitro
and in vivo. Oncol Rep. 30:731–738. 2013.PubMed/NCBI
|
|
33
|
Xu L, Yang D, Wang S, Tang W, Liu M, Davis
M, Chen J, Rae JM, Lawrence T and Lippman ME: (-)-Gossypol enhances
response to radiation therapy and results in tumor regression of
human prostate cancer. Mol Cancer Ther. 4:197–205. 2005.PubMed/NCBI
|
